{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:28Z","timestamp":1792088068774,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,4]],"date-time":"2027-06-04T00:00:00Z","timestamp":1812067200000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH Library","doi-asserted-by":"publisher","award":["R01DK111430"],"award-info":[{"award-number":["R01DK111430"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH Library","doi-asserted-by":"publisher","award":["R01CA230631"],"award-info":[{"award-number":["R01CA230631"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH Library","doi-asserted-by":"publisher","award":["R01CA259581"],"award-info":[{"award-number":["R01CA259581"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016471","name":"Agios Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"ALSAC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cell Biology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tcb.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:02:16Z","timestamp":1762207336000},"page":"471-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Understanding and targeting erythroid cell metabolism"],"prefix":"10.1016","volume":"36","author":[{"given":"Min","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Scaramellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1988-7337","authenticated-orcid":false,"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcb.2025.10.001_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOH.0b013e3282f97ae1","article-title":"Ontogeny of erythropoiesis","volume":"15","author":"Palis","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0010","article-title":"Red blood cell metabolism in vivo and in vitro","volume":"13","author":"D'Alessandro","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.tcb.2025.10.001_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2024.104153","article-title":"Metabolic regulation of erythrocyte development and disorders","volume":"131","author":"Lyu","year":"2024","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.3814","article-title":"Anemia: progress in molecular mechanisms and therapies","volume":"21","author":"Sankaran","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.tcb.2025.10.001_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.adh9215","article-title":"A glutamine metabolic switch supports erythropoiesis","volume":"386","author":"Lyu","year":"2024","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.tcb.2025.10.001_bb0030","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa2116634","article-title":"Mitapivat versus placebo for pyruvate kinase deficiency","volume":"386","author":"Al-Samkari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tcb.2025.10.001_bb0035","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(22)00214-9","article-title":"Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial","volume":"9","author":"Glenth\u00f8j","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0040","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood.2022015403","article-title":"A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease","volume":"140","author":"Xu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0045","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2019-121889","article-title":"Phase 1 single (SAD) and multiple ascending dose (MAD) studies of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of FT-4202, an allosteric activator of pyruvate kinase-R, in healthy and sickle cell disease subjects","volume":"134","author":"Kalfa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(22)01337-X","article-title":"Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent \u03b1-thalassaemia or \u03b2-thalassaemia: an open-label, multicentre, phase 2 study","volume":"400","author":"Kuo","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.tcb.2025.10.001_bb0055","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(24)00319-3","article-title":"Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial","volume":"12","author":"Idowu","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0060","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.stem.2010.07.011","article-title":"The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche","volume":"7","author":"Simsek","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tcb.2025.10.001_bb0065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.stem.2010.06.020","article-title":"Regulation of the HIF-1alpha level is essential for hematopoietic stem cells","volume":"7","author":"Takubo","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tcb.2025.10.001_bb0070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.tcb.2023.10.003","article-title":"Mitochondrial regulation in stem cells","volume":"34","author":"Wang","year":"2024","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0075","article-title":"Beyond ATP: metabolite networks as regulators of physiological and pathological erythroid differentiation","author":"Joly","year":"2024","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.tcb.2025.10.001_bb0080","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cell.2015.04.054","article-title":"Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock","volume":"161","author":"Mantel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.tcb.2025.10.001_bb0085","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/bloodadvances.2020003658","article-title":"Using mitochondrial activity to select for potent human hematopoietic stem cells","volume":"5","author":"Qiu","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.tcb.2025.10.001_bb0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exphem.2017.02.003","article-title":"Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease","volume":"50","author":"Jagadeeswaran","year":"2017","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0095","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjh.18287","article-title":"Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease","volume":"198","author":"Moriconi","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.stem.2014.06.002","article-title":"Glucose and glutamine metabolism regulate human hematopoietic stem cell lineage specification","volume":"15","author":"Oburoglu","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tcb.2025.10.001_bb0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MOH.0000000000000234","article-title":"Metabolic regulation of hematopoietic stem cell commitment and erythroid differentiation","volume":"23","author":"Oburoglu","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0110","doi-asserted-by":"crossref","first-page":"ra34","DOI":"10.1126\/scisignal.aaa5903","article-title":"The mTORC1\/4E-BP pathway coordinates hemoglobin production with L-leucine availability","volume":"8","author":"Chung","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tcb.2025.10.001_bb0115","first-page":"2520","article-title":"Arginine metabolism regulates human erythroid differentiation through hypusination of eIF5A","volume":"141","author":"Gonzalez-Menendez","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0120","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/ncb3527","article-title":"Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation","volume":"19","author":"Liu","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0125","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tcb.2025.10.001_bb0130","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1073\/pnas.88.2.522","article-title":"Glutamine synthetase gene evolution: a good molecular clock","volume":"88","author":"Pesole","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.tcb.2025.10.001_bb0135","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa050456","article-title":"Congenital glutamine deficiency with glutamine synthetase mutations","volume":"353","author":"H\u00e4berle","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tcb.2025.10.001_bb0140","article-title":"Minireview on glutamine synthetase deficiency, an ultra-rare inborn error of amino acid biosynthesis","volume":"5","author":"Spodenkiewicz","year":"2016","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.tcb.2025.10.001_bb0145","article-title":"Clinical metabolic understanding of human erythropoiesis","volume":"386","author":"Porta","year":"2025","journal-title":"eLetter Sci."},{"key":"10.1016\/j.tcb.2025.10.001_bb0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1203\/00006450-199202000-00010","article-title":"Studies on urea cycle enzyme levels in the human fetal liver at different gestational ages","volume":"31","author":"Mukarram Ali Baig","year":"1992","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.tcb.2025.10.001_bb0155","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2007-04-081703","article-title":"Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease","volume":"111","author":"Morris","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0160","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2017007187","article-title":"Red blood cells in hemorrhagic shock: a critical role for glutaminolysis in fueling alanine transamination in rats","volume":"1","author":"Reisz","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.tcb.2025.10.001_bb0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.V45.1.45.45","article-title":"Inhibition of sickling in erythrocytes by amino acids","volume":"45","author":"Rumen","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-2143(97)90062-7","article-title":"Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells","volume":"130","author":"Niihara","year":"1997","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.tcb.2025.10.001_bb0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","article-title":"Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential","volume":"58","author":"Niihara","year":"1998","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0180","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tcb.2025.10.001_bb0185","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2018-03-834440","article-title":"l-Glutamine for sickle cell anemia: more questions than answers","volume":"132","author":"Quinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0190","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/blood-2018-01-829036","article-title":"Glutamine via \u03b1-ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis","volume":"132","author":"Burch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MOH.0b013e3280de2bf1","article-title":"Molecular insights into stress erythropoiesis","volume":"14","author":"Socolovsky","year":"2007","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0200","article-title":"Metabolic regulation of stress erythropoiesis, outstanding questions, and possible paradigms","volume":"13","author":"Ruan","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0205","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.26923","article-title":"In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction","volume":"98","author":"D'Alessandro","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0210","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3324\/haematol.2023.283288","article-title":"Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment","volume":"108","author":"D'Alessandro","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.tcb.2025.10.001_bb0215","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejh.13424","article-title":"Prevalence of pyruvate kinase deficiency: a systematic literature review","volume":"105","author":"Secrest","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0220","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.2019000945","article-title":"Management of pyruvate kinase deficiency in children and adults","volume":"136","author":"Grace","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0225","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2019000944","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"136","author":"Luzzatto","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0230","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7326\/0003-4819-103-2-245","article-title":"Hemolytic anemias and erythrocyte enzymopathies","volume":"103","author":"Valentine","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tcb.2025.10.001_bb0235","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"Collaborators","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOH.0000000000000574","article-title":"Erythrocyte adaptive metabolic reprogramming under physiological and pathological hypoxia","volume":"27","author":"D'Alessandro","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12086","article-title":"Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia","volume":"7","author":"Sun","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tcb.2025.10.001_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13667-8","article-title":"Structural and functional insight of sphingosine 1-phosphate-mediated pathogenic metabolic reprogramming in sickle cell disease","volume":"7","author":"Sun","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tcb.2025.10.001_bb0255","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1182\/blood-2010-07-299636","article-title":"Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome","volume":"117","author":"Darghouth","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0260","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(11)60283-3","article-title":"Thalassaemia","volume":"379","author":"Higgs","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.tcb.2025.10.001_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102619","article-title":"Global, regional, and national burden of thalassemia, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"72","author":"Tuo","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tcb.2025.10.001_bb0270","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1182\/blood-2019-129996","article-title":"Decreased activity and stability of pyruvate kinase in hereditary hemolytic anemia: a potential target for therapy by AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase","volume":"134","author":"Rab","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0275","doi-asserted-by":"crossref","first-page":"13663","DOI":"10.1016\/S0021-9258(18)68292-4","article-title":"ATP-dependent proteolysis of hemoglobin alpha chains in beta-thalassemic hemolysates is ubiquitin-dependent","volume":"263","author":"Shaeffer","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tcb.2025.10.001_bb0280","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/bjh.17524","article-title":"Dried blood spot metabolomics reveals a metabolic fingerprint with diagnostic potential for Diamond Blackfan anaemia","volume":"193","author":"van Dooijeweert","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109172","article-title":"Disruption of mitochondrial energy metabolism is a putative pathogenesis of Diamond-Blackfan anemia","volume":"27","author":"Xiao","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.tcb.2025.10.001_bb0290","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/ajh.27300","article-title":"Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients: a proof-of-concept study","volume":"99","author":"Fattizzo","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0295","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.3390\/cancers12123520","article-title":"Bioenergetic profiling of the differentiating human MDS myeloid lineage with low and high bone marrow blast counts","volume":"12","author":"Poulaki","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tcb.2025.10.001_bb0300","first-page":"2535","article-title":"Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in \u03b2-thalassemic mice","volume":"108","author":"Matt\u00e8","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.tcb.2025.10.001_bb0305","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1182\/bloodadvances.2024013591","article-title":"Mitapivat metabolically reprograms human \u03b2-thalassemic erythroblasts, increasing their responsiveness to oxidation","volume":"9","author":"Siciliano","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.tcb.2025.10.001_bb0310","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(25)00635-X","article-title":"Mitapivat in adults with non-transfusion-dependent \u03b1-thalassaemia or \u03b2-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial","volume":"406","author":"Taher","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.tcb.2025.10.001_bb0315","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2006-02-004812","article-title":"Correction of sickle cell disease by homologous recombination in embryonic stem cells","volume":"108","author":"Wu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2022.102660","article-title":"Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model","volume":"95","author":"Quezado","year":"2022","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.tcb.2025.10.001_bb0325","first-page":"2639","article-title":"Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease","volume":"109","author":"D'Alessandro","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.tcb.2025.10.001_bb0330","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.278.5339.876","article-title":"Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease","volume":"278","author":"Paszty","year":"1997","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.tcb.2025.10.001_bb0335","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/bloodadvances.2020003604","article-title":"FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice","volume":"5","author":"Shrestha","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.tcb.2025.10.001_bb0340","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1182\/bloodadvances.2023012467","article-title":"Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease","volume":"8","author":"Saraf","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.tcb.2025.10.001_bb0345","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2024-203509","article-title":"Results from a phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of tebapivat (AG-946) in patients with sickle cell disease","volume":"144","author":"Xu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0350","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1182\/blood-2024-203073","article-title":"A phase 2B, open-label multicenter study of tebapivat (AG-946), a potent pyruvate kinase activator, in patients with anemia due to lower-risk myelodysplastic syndromes","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tcb.2025.10.001_bb0355","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ajh.27644","article-title":"Pyruvate kinase function correlates with red blood cell properties and clinical manifestations in sickle cell disease","volume":"100","author":"Traets","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0360","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/ajh.27442","article-title":"Mitapivat for phosphofructokinase deficiency","volume":"99","author":"Al-Samkari","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083691","article-title":"Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias - pilot study protocol","volume":"14","author":"Glenth\u00f8j","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.tcb.2025.10.001_bb0370","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.172656","article-title":"Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis","volume":"8","author":"Matte","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.tcb.2025.10.001_bb0375","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4397150","article-title":"Double-blind clinical trial of arginine supplementation in the treatment of adult patients with sickle cell anaemia","volume":"2019","author":"Eleut\u00e9rio","year":"2019","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0380","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.phoj.2020.05.002","article-title":"Comparative therapeutic effect of the L-arginine and sildenafil on beta-thalassemia children with increased tricuspid regurgitant jet velocity","volume":"5","author":"Ahmed El-Masry","year":"2020","journal-title":"Pediatr. Hematol. Oncol. J."},{"key":"10.1016\/j.tcb.2025.10.001_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28748","article-title":"L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: results from a multicenter pilot phase I\/II study from the Diamond-Blackfan Anemia Registry","volume":"67","author":"Vlachos","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.tcb.2025.10.001_bb0390","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.3324\/haematol.2018.190447","article-title":"L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients","volume":"103","author":"Bello","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.tcb.2025.10.001_bb0395","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjh.17479","article-title":"Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent \u03b2-thalassaemia","volume":"194","author":"Taher","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tcb.2025.10.001_bb0400","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2023-173821","article-title":"A phase I\/II, intra-patient dose-escalation study of bitopertin, a selective inhibitor of GlyT1 and heme synthesis, for steroid-refractory Diamond-Blackfan anemia","volume":"142","author":"Young","year":"2023","journal-title":"Blood"}],"container-title":["Trends in Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0962892425002247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0962892425002247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:45:02Z","timestamp":1780584302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0962892425002247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0962892425002247"],"URL":"https:\/\/doi.org\/10.1016\/j.tcb.2025.10.001","relation":{},"ISSN":["0962-8924"],"issn-type":[{"value":"0962-8924","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding and targeting erythroid cell metabolism","name":"articletitle","label":"Article Title"},{"value":"Trends in Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcb.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}